IN Shenzhen, the Credit Lyonnais B Index rose 1.4 per cent to 1,223.05 points on trading worth HK$18 million.
Trading was dominated by Lizhu Pharmaceutical, which rose 1.2 per cent to $4.30 on turnover of $10.82 million.
Lizhu's main product Lizhudele enjoys an 80 per cent share of China's anti-ulcer drug market, according to Crosby Securities.
Crosby is forecasting sustainable earnings growth of 20 per cent a year for the next three years, saying China's expanding pharmaceutical industry should ensure growing profits.
Lizhu recently gained approval to convert a portion of its A shares into B shares and also is planning a 3-for-10 rights issue.
Port developer Chiwan Wharf rebounded from recent falls, rising 4.4 per cent to $4.70.